

Author: Vaz-da-Silva Manuel Loureiro Ana I. Nunes Teresa Maia Joana Tavares Susana Falcão Amilcar Silveira Pedro Almeida Luis Soares-da-Silva Patricio
Publisher: Adis International
ISSN: 1173-2563
Source: Clinical Drug Investigation, Vol.25, Iss.6, 2005-01, pp. : 391-399
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Objective: To investigate the relative bioavailability and bioequivalence, in fasting and fed conditions, of repeated doses of two omeprazole enteric-coated formulations in healthy volunteers.Material and methods: Open label, single-centre study consisting of two consecutive randomised, two-way crossover trials (a fasting trial and a fed trial). Each trial consisted of two 7-day treatment periods in which subjects received one daily dose of the test (Ompranyt®) or reference (Mopral®) formulations. At day 7 and day 14 (fasting trial), products were administered in fasting conditions and blood samples were taken for omeprazole plasma assay over 12 hours. At day 21 and day 28 (fed trial), products were administered after a standard high-calorie and high-fat meal and 12-hour blood samples taken. Omeprazole plasma concentrations were quantified by a validated method using a reverse-phase high performance liquid chromatography with UV detection (HPLC-UV).Results: Twenty-four subjects were enrolled and 23 completed the study. Under fasting conditions, the mean ± SD maximum omeprazole plasma concentration (Cmax) was 797 ± 471 g/L for Ompranyt® and 747 ± 313
g/L for Mopral® with a point estimate (PE) of 1.01 and a 90% confidence interval (CI) of 0.88, 1.16. The mean ± SD area under the plasma concentration curve from administration to last observed concentration (AUC0-12) was 1932 ± 1611
g · h/L and 1765 ± 1327
g · h/L for Ompranyt® and Mopral®, respectively (PE = 1.09; 90% CI 0.95, 1.25). In the presence of food, the Cmax was 331 ± 227
g/L and 275 ± 162
g/L (PE = 1.21; 90% CI 0.92, 1.59) and AUC0-12 was 1250 ± 966
g · h/L and 1087 ± 861
g · h/L (PE = 1.16; 90% CI 0.92, 1.47) for Ompranyt® and Mopral®, respectively. Bioequivalence of the formulations in the fasting condition was demonstrated both for AUC0-12 and for Cmax because the 90% CI lay within the acceptance range of 0.801.25. In contrast with the fasting condition, there were significant reductions in rate (Cmax) and extent (AUC0-12) of systemic exposure when test and reference formulations were administered with food. The food effect was more marked with Mopral® than with Ompranyt®, and the bioequivalence criterion was not fulfilled because the 90% CI fell out of the acceptance range of 0.80, 1.25, for both Cmax and AUC0-12. The two formulations were similarly well tolerated.Conclusion: Bioequivalence of Ompranyt® (test formulation) and Mopral® (reference) formulations was demonstrated after repeated dosing in the fasting condition. Following a high-calorie and high-fat meal, there was a significant reduction in rate and extent of systemic exposure for both products, with Ompranyt® being less affected than Mopral® by the presence of food.
Related content




By Vaz-da-Silva M. Hainzl D. Almeida L. Dolgner A. Silveira P. Maia J. Soares-da-Silva P.
Clinical Drug Investigation, Vol. 21, Iss. 3, 2001-03 ,pp. :


By EL-Badry Mahmoud Alanazi Fars K. Mahrous Gamal M. Alsarra Ibrahim A.
Pharmaceutical Development and Technology, Vol. 15, Iss. 5, 2010-10 ,pp. :

